Revised Korean society of infectious diseases/national evidence-based healthcarea collaborating agency guidelines on the treatment of patients with COVID-19

22Citations
Citations of this article
60Readers
Mendeley users who have this article in their library.

Abstract

Despite the global effort to mitigate the spread, coronavirus disease 2019 (COVID-19) has become a pandemic that took more than 2 million lives. There are numerous ongoing clinical studies aiming to find treatment options and many are being published daily. Some effective treatment options, albeit of variable efficacy, have been discovered. Therefore, it is necessary to develop an evidence-based methodology, to continuously check for new evidence, and to update recommendations accordingly. Here we provide guidelines on pharmaceutical treatment for COVID-19 based on the latest evidence.

Cite

CITATION STYLE

APA

Kim, S. B., Ryoo, S., Huh, K., Joo, E. J., Kim, Y. J., Choi, W. S., … Yeom, J. S. (2021). Revised Korean society of infectious diseases/national evidence-based healthcarea collaborating agency guidelines on the treatment of patients with COVID-19. Infection and Chemotherapy, 53(1), 166–219. https://doi.org/10.3947/IC.2021.0303

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free